ALLR - CIK 0001860657
The table below shows Allarity Therapeutics, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | -$2.27M | - | - |
| R&D | $6.60M | $6.10M | $7.10M | $6.93M | $14.20M | $4.22M |
| SG&A | $6.32M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $11.44M |
| $10.03M |
| $9.96M |
| $12.36M |
| $4.10M |
| Operating income | -$12.61M | -$27.24M | -$17.13M | -$34.46M | -$26.56M | -$8.32M |
| Income tax | $0.00 | -$381.00K | $83.00K | -$1.52M | $133.00K | $198.00K |
| Net income | -$11.23M | -$24.52M | -$11.90M | -$16.06M | -$26.65M | -$6.62M |
| EPS (diluted) | - | - | -$10.26 | -$3.09K | -$4.19 | - |